The incidence of the epidemiological markers of allergy in adults;Erişkinlerdeki Alerjilerde Epidemiyolojik Göstergelerin i̇nsidans

Journal of Clinical and Analytical Medicine

Volumn 5, Issue 2, 2014, Pages 138-143

  Yalcin, Arzu Didem ^a   Bisgin, Atil ^b   Polat, Hasan Huseyin ^c  

^a Orthopaedics and Traumatology Clinic   (Turkey)

^b AKDENIZ UNIVERSITY   (Turkey)

^c CUMHURIYET UNIVERSITY   (Turkey)

Author keywords

Allergens; Allergic asthma; Allergic conjunctivitis; Allergic rhinitis; Subcuta neous specific allergen immunotherapy

Indexed keywords

ALLERGEN; IMMUNOGLOBULIN E;

ADULT; AGE; AIR POLLUTION; ALLERGIC ASTHMA; ALLERGIC RHINITIS; ANTIBODY SPECIFICITY; ANTIGEN SPECIFICITY; ARTICLE; ASTHMA; CEREAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE EXACERBATION; DISEASE MARKER; ENZYME IMMUNOASSAY; FEMALE; HOUSE DUST; HUMAN; IMMUNOLOGY TEST KIT; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOULD; PLANT; PRICK TEST; RHINOCONJUNCTIVITIS; SMOKING; SUBCUTANEOUS IMMUNOTHERAPY; SYMPTOM; YOUNG ADULT;

EID: 84900027399     PISSN: 13090720     EISSN: 13092014     Source Type: Journal    
DOI: 10.4328/JCAM.1254     Document Type: Article

References (34)

1. Douglass JA, O'Hehir RE. 1. Diagnosis, treatment and prevention of allergic dis-ease: the basics. Med J Aust 2006 21;185 (4):228-33.
2. Pawankar R. Inflammatory mechanisms in allergic rhinitis. Curr Opin Allergy. Clin Immunol 2007;7:1-4.
3. Spergel JM. Atopic march: link to upper airways. Curr Opin Allergy Clin Immunol 2005; 5: 17-21.
4. Yalcin AD, Öncel S, Akcan A, Eravşar K, Polat HH, Terzioǧlu E. Prevalance of al-lergic asthma, rhinitis and conjunctivitis in over 16 year old individuals in Antalya. Turkiye Klinikleri J Med Sci 2010; 30(3):888-94
5. Von Hertzen L, Haahtela T. Disconnection of man and the soil: reason for the asthma and atopy epidemic? J Allergy Clin Immunol 2006; 117(2):334-44.
6. Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural pop-ulations: increasing prevalence with increasing urbanization. Allergy 2005; 60(11):1357-60.
7. Tariq SM, Matthews SM, Hakim EA, Stevens M, Arshad SH. The prevalence of and risk factors for atopy in early childhood: a whole population birth cohort study. J Allergy Clin Immunol 1998;101(5):587-93.
8. Cockburn IM, Bailit HL, Berndt ER, Finkelstein SN. Loss of work productivity due to illness and medical treatment. J Occup Environ Med 1999; 41(11):948-53.
9. Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. Allergy 2005;60(11):1357-60.
10. Tariq SM, Matthews SM, Hakim EA, Stevens M, Arshad SH, Hide DW. The prev-alence of and risk factors for atopy in early childhood: a whole population birth cohort study. J Allergy Clin Immunol 1998; 101(5):587-93.
11. Malone DC, Lawson KA, Smith DH, Okamoto LJ, Battista C, Saunders WB. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997;99:22-7
12. Rossi RE, Melioli G, Monasterolo G, Harwanegg C, Rossi L, Canonica GW, et al: Sensitization profiles in polysensitized patients from a restricted geographical area: further lessons from multiplexed component resolved diagnosis.Eur Ann Al-lergy Clin Immunol 2011;43(6):171-5.
13. Bener A, Safa W, Abdulhalik S, Lestringant GG. An analysis of skin prick test reactions in asthmatics in a hot climate and desert environment. Allerg Immunol 2002;34(8):281-6.
14. Arbes SJ Jr, Gergen Pj, Elliot L, Zeldin DC. Prevalences of positive skin test responses to 10 common allergens in the US population: results from the third National Health and Nutrition Examination Survey. J Allergy Clin Immunol 2005;116(2):377-83.
15. Gioulekas D, Papakosta D, Damialis A, Spieksma F, Giouleka P, Patakas D. Al-lergenic pollen records (15 years) and sensitization in patients with respiratory allergy in Thessaloniki, Greece. Allergy 2004;59(2):174-84.
16. Pata YS, Akbas Y, Unal M, Ozcan C, Görür K, Talas DU.Distribution of allergens among allergic rhinitis patients living in Mersin region. Kulak Burun Bogaz Ihtis Derg 2004;13(5-6):112-5.
17. Malone DC, Lawson KA, Smith DH, Arrighi HM, Battista C. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99:22-7.
18. Yazisiz V. Yalcin AD, Afacan B, Avci AB, Terzioǧlu E. Assessment of Patients With Allergic Rhinitis Living in Antalya Region. Asti{dotless}m Allerji İmmünoloji 2007;5(2):61-66.
19. Robbie-Ryan, M., and M. Brown. The role of mast cells in allergy and autoim-munity. Curr. Opin. Immunol. 2002;14: 728-733.
20. Berent-Maoz B, Piliponsky AM, Daigle I, Simon HU, Levi-Schaffer F. Human Mast Cells Undergo TRAIL-Induced Apoptosis. J Immunol 2006;176;2272-8.
21. Robbie-Ryan, M., and M. Brown. The role of mast cells in allergy and autoim-munity. Curr. Opin. Immunol 2002;14: 728-733.
22. Karaman O, Turgut CS, Uzuner N, Olmez D, Babayigit A, Kose S, Tezcan D., et al: The determination of asthma, rhinitis, eczema, and atopy prevalence in 9- to 11-year-old children in the city of Izmir. Allergy Asthma Proc 2006;27(4):319-24.
23. Dottorini ML, Bruni B, Peccini F, Bottini P, Pini L, Donato F., et al: Skin prick-test reactivity to aeroallergens and allergic symptoms in an urban population of central Italy: a longitudinal study. Clin Exp Allergy 2007;37(2):188-96.
24. Marinho S, Simpson A, Custovic A. Allergen avoidance in the secondary and tertiary prevention of allergic diseases: does it work? Prim Care Respir J 2006;15(3):152-8.
25. Puxeddu, I., A. M. Piliponsky, I. Bachelet, and F. Levi-Schaffer. Mast cells in al-lergy and beyond. Int. J. Biochem. Cell Biol 2003; 35: 1601-1607.
26. Melvin TA, Patel AA: Pharmacotherapy for allergic rhinitis. Otolaryngol Clin North Am 2011;44:727-39.
27. Gautrin D, Malo JL: Risk factors, predictors, and markers for work-related asthma and rhinitis. Curr Allergy Asthma Rep 2010;10:365-72.
28. Gratziou C, Rovina N, Makris M, Simoes DC, Papapetropoulos A, Roussos C: Breath markers of oxidative stress and airway inflammation in Seasonal Allergic Rhinitis. Int J Immunopathol Pharmacol 2008;21:949-57.
29. Yalcin AD, Bisgin A, Kargi A, Gorczynski RM. Serum soluble TRAIL levels in patients with severe persistent allergic asthma: its relation to Omalizumab treat-ment. ID:16729 Med Sci Monit 2012; 18 (3): PI 11-5.
30. Yalcin AD, Bisgin A. The Relation of sTRAIL Levels and Quality of Life In Omali-zumab Using Severe Persistent Allergic Asthma Patients. ID:18276 Med Sci Monit 2012;18(8);LE9-10.
31. Yalcin AD, Gorczynski RM, Parlak GE, Kargi A, Bisgin A, Kose S, et al: Total antioxidant capacity, hydrogen peroxide, malondialdehyde and total nitric oxide concentrations in patients with severe persistent allergic asthma: its relation to omalizumab treatment. Clin Lab 2012;58(1-2):89-96.
32. Yalcin AD, Gumuslu S, Parlak GE, Bisgin A, Yilmaz M, Kargi A, et al: Systemic Levels Of Ceruloplasmin Oxidase Activity In Allergic Asthma And Allergic Rhinitis. Immunopharmacology And Immunotoxicology. DOI:10,3109/08923973,2012.697 902.
33. Yalcin AD, Gumuslu S, Parlak GE, Gorczynski RM. Soluble TRAIL as a marker of efficacy of allergen-spesific immunotherapy in patients with allergic rhinoconjunc-tivitis (accepted 29/05/2012). ID:17944, Med Sci Monit 2012;18(10);
34. Yalcin AD, Basaran S, Polat HH, Bisgin A, Gorczynski RM. Pollen aero allergens and the climate in Mediterranean region of Turkey and allergen sensitivity in al-lergic rhinoconjunctivitis and allergic asthma patients. Medical science monitor: international medical journal of experimental and clinical research. (accepted 9/7/2012). ID:17710, Med Sci Monit 2013;19(2):